# US 2008/0305187 A1 · Use of Parathyroid Hormone for Treating Periodontal Disease and for Other Dental Applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305187 A1
- Document ID: US20080305187A1
- Status: Published application
- Kind: A1
- Application number: 12/094,309
- Filed: 2006-12-19
- Published: 2008-12-11
- Earliest claimed: 2005-12-20
- Inventors: John Henry Krege
- Web page: https://patentgrep.com/patent/US20080305187A1

## CPC

- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 19/00: Drugs for skeletal disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Method for treating or preventing periodontal disease associated with mild to severe alveolar bone loss, and for improving the prognosis of dental implant procedures by administering human parathyroid hormone to a patient in need thereof.

## Claims

### Claim 1

A method for the treatment of periodontal disease in a human patient comprising administration of human parathyroid hormone in a daily dose of 20 μg to 30 μg.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method as in claim 1 wherein said treatment restores lost alveolar bone at one or more affected tooth sockets following tooth extraction.

### Claim 4 (depends on 1)

The method as in claim 1 wherein said treatment reduces pocket probing depth.

### Claim 5 (depends on 1)

The method as in claim 1 wherein said treatment increases alveolar BMD.

### Claim 6 (depends on 1)

The method as in claim 1 wherein said periodontal disease is selected from the group consisting of juvenile periodontitis, adult periodontitis, necrotizing ulcerative gingivo-periodontitis, refractory periodontitis, early-onset periodontitis, aggressive periodontitis, and periodontitis associated with systemic disease.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method as in claim 1 said treatment further comprising co-administering an agent selected from the group consisting of vitamin D, calcium, estrogen, hormone replacement therapy, bisphosphonate, calcitonin, and SERM.

### Claim 9 (depends on 1)

The method as in claim 1 wherein said treatment with parathyroid hormone is for a period of one month to 24 months, and wherein at the end of said treatment period one or more other agents are administered, selected from the group consisting of vitamin D, calcium, estrogen, hormone replacement therapy, calcitonin, bisphosphonate, and SERM.

### Claim 10 (depends on 1)

The method as in claim 1 wherein said parathyroid hormone is selected from the group consisting of PTH(1-28), PTH(1-31), PTH(1-34), PTH(1-37), PTH(1-38), PTH(1-41) and PTH(1-84).

### Claim 11 (depends on 1)

The method as in claim 1 wherein said parathyroid hormone is administered parentally.

### Claim 12 (depends on 1)

The method as in claim 1 wherein said parathyroid hormone is PTH(1-34) and said daily dose is 20 μg.

### Claim 13 (depends on 1)

The method as in claim 1 wherein said treatment increases bone mass.

### Claim 14 (depends on 1)

The method as in claim 1 wherein said treatment improves bone structure.

### Claim 15 (depends on 1)

The method as in claim 1 wherein said treatment stabilizes one or more teeth.

### Claim 16 (depends on 1)

The method as in claim 1 wherein said treatment reduces further bone loss at said tooth socket.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The method as in claim 1 wherein said parathyroid hormone is administered by local injection at or near said tooth socket.

### Claim 19

A method to improve the prognosis of a dental implant procedure in a patient having inadequate alveolar bone mass, comprising administering human parathyroid hormone to said patient at a daily dose of 20 μg to 30 μg for a period of from about 3 months to about 6 months prior to said procedure.

### Claim 20

A method to accelerate osseointegration of a dental implant in a patient following placement of an implant, comprising administration of human parathyroid hormone at a daily dose of 20 μg to 30 μg.
